News

News

October 26, 2020
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GSK to pay one-time cash payment of
September 11, 2020
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
SAN DIEGO , Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio , Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will
August 5, 2020
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio , Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will
July 31, 2020
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement SAN DIEGO , July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms
July 15, 2020
AnaptysBio Expands Executive Leadership Team
Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer SAN DIEGO , July 15, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune
Displaying 1 - 10 of 15